|
270 Companies |
|
374 Products |
|
374 Products |
|
160 Mechanisms of Action |
|
39 Trials |
|
5519 News |
|
| «12...1314151617181920212223...110111» |
- Lynparza (olaparib) / Merck (MSD), AstraZeneca
New trial: Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer. (clinicaltrials.gov) - Mar 13, 2017
P=N/A, N=0, Available, Sponsor: AstraZeneca
- | progesterone / Generic mfg., progesterone / Generic mfg.
New P2/3 trial: Cerclage for Twins With Short Cervix (clinicaltrials.gov) - Mar 12, 2017
P2/3, N=152, Not yet recruiting, Sponsor: Mednax Center for Research, Education and Quality
- | Phase classification, Trial primary completion date: Emerging Adults Who Use Alcohol and Marijuana (clinicaltrials.gov) - Mar 10, 2017
P3, N=566, Active, not recruiting, Sponsor: Butler Hospital
Phase classification: P4 --> P3 | Trial primary completion date: Aug 2016 --> Aug 2017
- | triptorelin / Generic mfg.
Preclinical, Enrollment change, Trial primary completion date: Effect of Prolonged GnRh Agonists on Results of Intracytoplasmic Sperm Injection (ICSI ) in Endometrioma Patients (clinicaltrials.gov) - Mar 10, 2017
P=N/A, N=88, Recruiting, Sponsor: Kasr El Aini Hospital
Phase classification: P4 --> P3 | Trial primary completion date: Aug 2016 --> Aug 2017 N=60 --> 88 | Trial primary completion date: Aug 2016 --> Apr 2017
- | Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Trial primary completion date, Metastases: Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer (clinicaltrials.gov) - Mar 10, 2017
P2, N=299, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=60 --> 88 | Trial primary completion date: Aug 2016 --> Apr 2017 Trial primary completion date: Jun 2016 --> Sep 2017
- | Votrient (pazopanib) / Novartis, BeiGene
Trial completion, Phase classification, Combination therapy: PAZPET-1: [18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer (clinicaltrials.gov) - Mar 10, 2017
P1b, N=16, Completed, Sponsor: Imperial College London
Trial primary completion date: Jun 2016 --> Sep 2017 Active, not recruiting --> Completed | Phase classification: P1 --> P1b
- | valacyclovir / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2 (clinicaltrials.gov) - Mar 9, 2017
P4, N=50, Completed, Sponsor: University of Washington
Active, not recruiting --> Completed | Phase classification: P1 --> P1b Active, not recruiting --> Completed | N=82 --> 50 | Trial primary completion date: Sep 2011 --> Jul 2010
- | New P3 trial, Biopsy: Effects of Lidocaine Spray for Reducing Pain During Endometrial Aspiration Biopsy : a Randomized Controlled Trial (clinicaltrials.gov) - Mar 9, 2017
P3, N=240, Recruiting, Sponsor: Chiang Mai University
- | acyclovir / Generic mfg.
Trial completion, Trial primary completion date: A Randomized Trial to Evaluated the Suppressive Effect of Acyclovir on Rapidly Cleared HSV-2 Reactivation (clinicaltrials.gov) - Mar 9, 2017
P4, N=48, Completed, Sponsor: University of Washington
Active, not recruiting --> Completed | N=82 --> 50 | Trial primary completion date: Sep 2011 --> Jul 2010 Active, not recruiting --> Completed | Trial primary completion date: Sep 2011 --> Jul 2010
- | New trial: Screening of Gonococcal and Chlamydial Infections in the Third Trimester (clinicaltrials.gov) - Mar 8, 2017
P=N/A, N=1000, Enrolling by invitation, Sponsor: St. Michael's Hospital, Toronto
- | Phase classification, Trial primary completion date, HEOR: AdolCHICA: Improving Adolescent Health Outcomes Through Preventive Care Transformation (clinicaltrials.gov) - Mar 7, 2017
P=N/A, N=2831, Recruiting, Sponsor: Indiana University
Active, not recruiting --> Completed | Trial primary completion date: Sep 2011 --> Jul 2010 Phase classification: P2 --> P=N/A | Trial primary completion date: Oct 2016 --> Sep 2017
- | Trial completion, Enrollment change, Trial primary completion date: Taking Care of Her Program in Patients With Stage III or IV Ovarian Cancer and Spouse Caregivers (clinicaltrials.gov) - Mar 7, 2017
P=N/A, N=14, Completed, Sponsor: University of Washington
Phase classification: P2 --> P=N/A | Trial primary completion date: Oct 2016 --> Sep 2017 Recruiting --> Completed | N=64 --> 14 | Trial primary completion date: Aug 2017 --> Jun 2016
- | progesterone / Generic mfg.
Trial primary completion date: Progesterone Diurnal Rhythm During Ovarian Stimulation for IVF (clinicaltrials.gov) - Mar 7, 2017
P=N/A, N=12, Not yet recruiting, Sponsor: IVI Middle East Fertility Clinic
Recruiting --> Completed | N=64 --> 14 | Trial primary completion date: Aug 2017 --> Jun 2016 Trial primary completion date: Mar 2017 --> Aug 2017
- ||| Avastin (bevacizumab) / Roche
New trial, Combination therapy, Metastases: A Study to Evaluate Safety and Effectiveness of Bevacizumab in Combination With Paclitaxel and Cisplatin/Carboplatin or Toptecan in Participants With Advanced Cervical Cancer (clinicaltrials.gov) - Mar 7, 2017
P=N/A, N=120, Not yet recruiting, Sponsor: Hoffmann-La Roche
- | cisplatin / Generic mfg.
New P3 trial: A Trial Comparing Observation With Radiation on Pelvic Lymphocysts After Radical Hysterectomy of Cervical Cancer (clinicaltrials.gov) - Mar 6, 2017
P3, N=540, Not yet recruiting, Sponsor: Sun Yat-sen University
- Kevetrin (thioureidobutyronitrile) / Innovation Pharma
Enrollment open: A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer (clinicaltrials.gov) - Mar 5, 2017
P2, N=10, Recruiting, Sponsor: Cellceutix Corporation
Trial primary completion date: Mar 2017 --> Aug 2017 Active, not recruiting --> Recruiting
- | progesterone / Generic mfg.
Trial completion: Subcutaneous Progesterone Versus Vaginal Progesterone for Endometrial Preparation in Fresh Donated Oocytes Recipients (clinicaltrials.gov) - Mar 3, 2017
P4, N=120, Completed, Sponsor: Instituto Bernabeu
Active, not recruiting --> Recruiting Recruiting --> Completed
- || Enrollment closed: Evaluation of the Use of the Colli-Pee Device to Collect First-void Urine for Molecular Detection of STIs (clinicaltrials.gov) - Mar 3, 2017
P=N/A, N=186, Active, not recruiting, Sponsor: Institute of Tropical Medicine, Belgium
Recruiting --> Completed Recruiting --> Active, not recruiting
- | Trial completion: Evaluation of Modified Treatment Regimens for Treatment of Heavy Menstrual Bleeding Using the HerOption® System (clinicaltrials.gov) - Mar 2, 2017
P4, N=82, Completed, Sponsor: CooperSurgical Inc.
Recruiting --> Active, not recruiting Recruiting --> Completed
- | Trial completion: Understanding Adaptive Challenges Associated With Male-factor Infertility (clinicaltrials.gov) - Mar 1, 2017
P=N/A, N=24, Completed, Sponsor: Duke University
Recruiting --> Completed Active, not recruiting --> Completed
- orteronel (TAK 700) / Takeda
Enrollment change, Trial termination, Metastases: Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors. The Greko II Study. (clinicaltrials.gov) - Mar 1, 2017
P2, N=10, Terminated, Sponsor: Grupo Español de Tumores Huérfanos e Infrecuentes
Active, not recruiting --> Completed N=20 --> 10 | Recruiting --> Terminated; Slow recruitment rate
- Trial primary completion date, Surgery: Antimullerian Hormone in Endometriomas (clinicaltrials.gov) - Feb 27, 2017
P=N/A, N=40, Recruiting, Sponsor: Hospital Universitari de Bellvitge
N=20 --> 10 | Recruiting --> Terminated; Slow recruitment rate Trial primary completion date: Dec 2016 --> Sep 2017
- | Trial initiation date, Trial primary completion date: PET-MRI for Functional Imaging of the Testis: A Feasibility Study (clinicaltrials.gov) - Feb 27, 2017
P=N/A, N=20, Not yet recruiting, Sponsor: New York University School of Medicine
Trial primary completion date: Dec 2016 --> Sep 2017 Initiation date: Oct 2016 --> Apr 2017 | Trial primary completion date: Jan 2017 --> Dec 2017
- | Trial completion: Friendship Based HIV/STI (Sexually Transmitted Infections) Intervention for African American Females (clinicaltrials.gov) - Feb 27, 2017
P=N/A, N=420, Completed, Sponsor: University of North Carolina, Chapel Hill
Initiation date: Oct 2016 --> Apr 2017 | Trial primary completion date: Jan 2017 --> Dec 2017 Recruiting --> Completed
- || Trial primary completion date: Clinical Evaluation of the BD Onclarity (clinicaltrials.gov) - Feb 27, 2017
P=N/A, N=33858, Completed, Sponsor: Becton, Dickinson and Company
Recruiting --> Completed Trial primary completion date: Sep 2015 --> Mar 2016
- | Enrollment change, Trial initiation date, Trial withdrawal, Trial primary completion date: PROMOTER: The Potential for HPV Self-testing to Promote Participation in Cervical Screening (clinicaltrials.gov) - Feb 24, 2017
P=N/A, N=0, Withdrawn, Sponsor: University Hospitals Coventry and Warwickshire NHS Trust
Trial primary completion date: Sep 2015 --> Mar 2016 N=6000 --> 0 | Initiation date: Jun 2016 --> Jan 2016 | Not yet recruiting --> Withdrawn | Trial primary completion date: Oct 2016 --> Jan 2017
- | Trial completion, Trial primary completion date: Homeopathic Treatment of Chronic Pelvic Pain in Women With Endometriosis (clinicaltrials.gov) - Feb 24, 2017
P4, N=50, Completed, Sponsor: University of Sao Paulo General Hospital
N=6000 --> 0 | Initiation date: Jun 2016 --> Jan 2016 | Not yet recruiting --> Withdrawn | Trial primary completion date: Oct 2016 --> Jan 2017 Active, not recruiting --> Completed | Trial primary completion date: Oct 2016 --> Feb 2016
- | New trial, Biopsy: The Transition From Blastomere to Trophectoderm Biopsy: Comparing Two PGS Strategies (clinicaltrials.gov) - Feb 24, 2017
P=N/A, N=383, Completed, Sponsor: Institut Universitari Dexeus
- | Folotyn (pralatrexate) / Aurobindo
Enrollment change: Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer (clinicaltrials.gov) - Feb 24, 2017
P2, N=50, Active, not recruiting, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed | Trial primary completion date: Oct 2016 --> Feb 2016 N=72 --> 50
- ||||||| Trial completion, Enrollment change, Trial primary completion date: A Randomized, Multicentre, Open Label, Evaluator Blinded Study to Evaluate Safety and Efficacy of Folitime (clinicaltrials.gov) - Feb 24, 2017
P3, N=106, Completed, Sponsor: Gema Biotech S.A.
N=72 --> 50 Recruiting --> Completed | N=88 --> 106 | Trial primary completion date: May 2016 --> Dec 2016
- | Trial primary completion date, HEOR: Peer-to-Peer Support Program in Improving Quality of Life Outcomes in Patients With Gynecologic Cancer and Their Caregivers (clinicaltrials.gov) - Feb 23, 2017
P=N/A, N=30, Recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Completed | N=88 --> 106 | Trial primary completion date: May 2016 --> Dec 2016 Trial primary completion date: Jul 2017 --> Jul 2018
- | hyoscine butylbromide oral / Generic mfg.
Phase classification: Antispasmodic Drug for Diagnosis Proximal Tubal Occlusion on Hysterosalpingography (clinicaltrials.gov) - Feb 23, 2017
P=N/A, N=72, Recruiting, Sponsor: Mahidol University
Trial primary completion date: Jul 2017 --> Jul 2018 Phase classification: P4 --> P=N/A
- | Eprex (epoetin alfa) / J&J
New trial: Proliferative Effects of Erythropoietin on Human Endometrium (clinicaltrials.gov) - Feb 23, 2017
P=N/A, N=20, Recruiting, Sponsor: Fatih Sultan Mehmet Training and Research Hospital
- | Phase classification, Enrollment change, Trial initiation date, Trial primary completion date: The Effect of the Nutraceutical "Hemofix" on the Coagulation System (clinicaltrials.gov) - Feb 23, 2017
P=N/A, N=0, Withdrawn, Sponsor: Hadassah Medical Organization
Phase classification: P4 --> P=N/A Phase classification: P1 --> P=N/A | N=40 --> 0 | Initiation date: Sep 2012 --> Sep 2016 | Trial primary completion date: Feb 2013 --> Jan 2020
- | Trial completion, Surgery: The Effect of Surgery for Non Endometriosic Ovarian Cysts on Ovarian Reserve (clinicaltrials.gov) - Feb 23, 2017
P=N/A, N=30, Completed, Sponsor: Corporacion Parc Tauli
Phase classification: P1 --> P=N/A | N=40 --> 0 | Initiation date: Sep 2012 --> Sep 2016 | Trial primary completion date: Feb 2013 --> Jan 2020 Recruiting --> Completed
- | trebananib (AMG 386) / Amgen
Trial termination, Combination therapy: TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer (clinicaltrials.gov) - Feb 23, 2017
P3, N=1015, Terminated, Sponsor: Amgen
Recruiting --> Completed Completed --> Terminated; Amgen Administrative Decision - termination of LTFU
- | Trial primary completion date, HEOR: Survivorship Care Planning in Improving Quality of Life in Survivors of Ovarian Cancer (clinicaltrials.gov) - Feb 23, 2017
P=N/A, N=14, Active, not recruiting, Sponsor: City of Hope Medical Center
Completed --> Terminated; Amgen Administrative Decision - termination of LTFU Trial primary completion date: Feb 2017 --> Nov 2017
- | Trial completion, Biopsy: Effectiveness of Paracervical Block Versus Lidocaine Spray During Endometrial Biopsy (clinicaltrials.gov) - Feb 23, 2017
P=N/A, N=120, Completed, Sponsor: Mahidol University
Trial primary completion date: Feb 2017 --> Nov 2017 Recruiting --> Completed
- | Preclinical, Trial primary completion date: Phase III Study Comparing Efficacy and Safety of AFOLIA vs Gonal-f® RFF in Women (35 to 42) Undergoing IVF (clinicaltrials.gov) - Feb 20, 2017
P3, N=1100, Active, not recruiting, Sponsor: Fertility Biotech AG
Recruiting --> Completed Trial primary completion date: Apr 2016 --> Jan 2017
- folate-tubulysin (EC1456) / Novartis
Enrollment open, Phase classification, Surgery: An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery (clinicaltrials.gov) - Feb 20, 2017
P1, N=30, Recruiting, Sponsor: Endocyte
Trial primary completion date: Apr 2016 --> Jan 2017 Not yet recruiting --> Recruiting | Phase classification: PN/A --> P1
- |||| lifastuzumab vedotin (DNIB0600A) / Roche
Trial completion, Trial primary completion date: A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC) (clinicaltrials.gov) - Feb 17, 2017
P2, N=95, Completed, Sponsor: Genentech, Inc.
Not yet recruiting --> Recruiting | Phase classification: PN/A --> P1 Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Aug 2016
- | Trial completion, Enrollment change, Trial primary completion date: Surgical Outcomes of Vaginal Prolapse Repair With Elevate (clinicaltrials.gov) - Feb 16, 2017
P=N/A, N=417, Completed, Sponsor: Larry Sirls
Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Aug 2016 Active, not recruiting --> Completed | N=100 --> 417 | Trial primary completion date: Dec 2017 --> Dec 2016
- | cabergoline / Generic mfg., calcium dobesilate monohydrate / Generic mfg.
Trial initiation date, Trial primary completion date: Calcium Dobesilate Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome (clinicaltrials.gov) - Feb 16, 2017
P2/3, N=200, Completed, Sponsor: Benha University
Active, not recruiting --> Completed | N=100 --> 417 | Trial primary completion date: Dec 2017 --> Dec 2016 Initiation date: Apr 2013 --> Apr 2014 | Trial primary completion date: Dec 2016 --> Dec 2015
- New trial, Preclinical: Myo-inositol/D-chiro-inositol Ratio in Follicular Fluid (clinicaltrials.gov) - Feb 16, 2017
P=N/A, N=34, Completed, Sponsor: Lo.Li.Pharma s.r.l
- |||| Invanz (ertapenem) / Merck (MSD)
Trial completion: An Investigational Agent for the Treatment of Complicated Intra-Abdominal Infections or Acute Pelvic Infections (0826-038) (clinicaltrials.gov) - Feb 16, 2017
P2, N=100, Completed, Sponsor: Merck Sharp & Dohme Corp.
Initiation date: Apr 2013 --> Apr 2014 | Trial primary completion date: Dec 2016 --> Dec 2015 No longer recruiting --> Completed
- Kevetrin (thioureidobutyronitrile) / Innovation Pharma
Enrollment closed: A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer (clinicaltrials.gov) - Feb 16, 2017
P2, N=10, Active, not recruiting, Sponsor: Cellceutix Corporation
No longer recruiting --> Completed Not yet recruiting --> Active, not recruiting
- | davamotecan pegadexamer (EP0057) / Ellipses Pharma, Avastin (bevacizumab) / Roche
Enrollment change, Trial primary completion date, Combination therapy: CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer (clinicaltrials.gov) - Feb 16, 2017
P2, N=63, Active, not recruiting, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Active, not recruiting N=29 --> 63 | Trial primary completion date: Apr 2016 --> Mar 2017
- ||| zabedosertib (BAY1834845) / Bayer
Clinical: First in Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and to Explore Pharmacodynamics of BAY1834845 (clinicaltrials.gov) - Feb 15, 2017
P1, N=80, Not yet recruiting, Sponsor: Bayer
- | cabergoline / Generic mfg., calcium dobesilate monohydrate / Generic mfg.
Trial completion: Calcium Dobesilate Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome (clinicaltrials.gov) - Feb 14, 2017
P2/3, N=200, Completed, Sponsor: Benha University
N=29 --> 63 | Trial primary completion date: Apr 2016 --> Mar 2017 Recruiting --> Completed
- | calcium dobesilate monohydrate / Generic mfg.
Trial completion: Calcium Dobesilate Versus Coasting for Prevention of Ovarian Hyperstimulation Syndrome (clinicaltrials.gov) - Feb 14, 2017
P2/3, N=200, Completed, Sponsor: khalid abd aziz mohamed
Recruiting --> Completed Recruiting --> Completed